消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2018 JSGE循证临床实践指南：炎症性肠病

2018-02-10 日本皮肤病协会 J Gastroenterol. 2018 Feb 10.

炎症性肠病溃疡性结肠炎克罗恩病

2018年2月，日本胃肠病学会(JSGE)发布了炎症性肠病指南。炎症性肠病是一种慢性疾病，主要涉及肠道，也可影响其他消化器官和场外器官。本文主要针对炎症性肠病的临床表现，诊断，一般治疗，治疗性干预措施，溃疡性结肠炎以及克罗恩病的治疗肠外并发症，癌症检查，特殊情况等内容提出了59个临床问题。

中文标题：

2018 JSGE循证临床实践指南：炎症性肠病

英文标题：

Evidence-based clinical practice guidelines for inflammatory bowel disease

发布机构：

日本皮肤病协会

发布日期：

2018-02-10

简要介绍：

2018年2月，日本胃肠病学会(JSGE)发布了炎症性肠病指南。炎症性肠病是一种慢性疾病，主要涉及肠道，也可影响其他消化器官和场外器官。本文主要针对炎症性肠病的临床表现，诊断，一般治疗，治疗性干预措施，溃疡性结肠炎以及克罗恩病的治疗肠外并发症，癌症检查，特殊情况等内容提出了59个临床问题。

 

拓展指南：与炎症性肠病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 JSGE循证临床实践指南：炎症性肠病)] GetToolGuiderByIdResponse(projectId=1, id=597961c001558037, title=2018 JSGE循证临床实践指南：炎症性肠病, enTitle=Evidence-based clinical practice guidelines for inflammatory bowel disease, guiderFrom=J Gastroenterol. 2018 Feb 10., authorId=null, author=, summary=2018年2月，日本胃肠病学会(JSGE)发布了炎症性肠病指南。炎症性肠病是一种慢性疾病，主要涉及肠道，也可影响其他消化器官和场外器官。本文主要针对炎症性肠病的临床表现，诊断，一般治疗，治疗性干预措施，溃疡性结肠炎以及克罗恩病的治疗肠外并发症，癌症检查，特殊情况等内容提出了59个临床问题。 , cover=, journalId=null, articlesId=null, associationId=1114, associationName=日本皮肤病协会, associationIntro=null, copyright=0, guiderPublishedTime=Sat Feb 10 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年2月，日本胃肠病学会(JSGE)发布了炎症性肠病指南。炎症性肠病是一种慢性疾病，主要涉及肠道，也可影响其他消化器官和场外器官。本文主要针对炎症性肠病的临床表现，诊断，一般治疗，治疗性干预措施，溃疡性结肠炎以及克罗恩病的治疗肠外并发症，癌症检查，特殊情况等内容提出了59个临床问题。 </P> <P> </P>拓展指南：<strong>与<font color=red>炎症性肠病</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=8d85c1c001510111" title="2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理" target=_blank>2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ab8d41c0015100be" title="2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估" target=_blank>2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9ef291c001509341" title="2017 共识声明：抗肿瘤坏死因子治疗炎症性肠病治疗药物监测" target=_blank>2017 共识声明：抗肿瘤坏死因子治疗炎症性肠病治疗药物监测</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2dc9f1c0015030f6" title="抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)" target=_blank>抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6c0a31c001a8e4da" title="建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见" target=_blank>建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E7%82%8E%E7%97%87%E6%80%A7%E8%82%A0%E7%97%85" target=_blank>有关炎症性肠病更多指南</a></ul>, tagList=[TagDto(tagId=1125, tagName=炎症性肠病), TagDto(tagId=7365, tagName=溃疡性结肠炎), TagDto(tagId=984, tagName=克罗恩病)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6996, appHits=296, showAppHits=0, pcHits=5078, showPcHits=2314, likes=127, shares=9, comments=8, approvalStatus=1, publishedTime=Thu Feb 22 20:40:51 CST 2018, publishedTimeString=2018-02-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Feb 22 20:40:51 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 14:06:54 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 JSGE循证临床实践指南：炎症性肠病)])
2018 JSGE循证临床实践指南：炎症性肠病
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=361063, encodeId=3f8936106357, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:41:25 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291430, encodeId=a1012914302c, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Feb 27 15:05:57 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291229, encodeId=75c629122964, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Feb 27 03:00:32 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290393, encodeId=dcda29039344, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 24 07:05:13 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290332, encodeId=cd8329033204, content=不错.学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=662c2267356, createdName=12198cffm94(暂无昵称), createdTime=Sat Feb 24 01:10:17 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2019-02-20 天天作西

    非常感谢！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=361063, encodeId=3f8936106357, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:41:25 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291430, encodeId=a1012914302c, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Feb 27 15:05:57 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291229, encodeId=75c629122964, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Feb 27 03:00:32 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290393, encodeId=dcda29039344, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 24 07:05:13 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290332, encodeId=cd8329033204, content=不错.学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=662c2267356, createdName=12198cffm94(暂无昵称), createdTime=Sat Feb 24 01:10:17 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2018-02-27 虈亣靌

    学习了.获益匪浅.感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=361063, encodeId=3f8936106357, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:41:25 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291430, encodeId=a1012914302c, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Feb 27 15:05:57 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291229, encodeId=75c629122964, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Feb 27 03:00:32 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290393, encodeId=dcda29039344, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 24 07:05:13 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290332, encodeId=cd8329033204, content=不错.学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=662c2267356, createdName=12198cffm94(暂无昵称), createdTime=Sat Feb 24 01:10:17 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2018-02-27 秀红

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=361063, encodeId=3f8936106357, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:41:25 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291430, encodeId=a1012914302c, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Feb 27 15:05:57 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291229, encodeId=75c629122964, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Feb 27 03:00:32 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290393, encodeId=dcda29039344, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 24 07:05:13 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290332, encodeId=cd8329033204, content=不错.学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=662c2267356, createdName=12198cffm94(暂无昵称), createdTime=Sat Feb 24 01:10:17 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2018-02-24 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=361063, encodeId=3f8936106357, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:41:25 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291430, encodeId=a1012914302c, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Feb 27 15:05:57 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291229, encodeId=75c629122964, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Feb 27 03:00:32 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290393, encodeId=dcda29039344, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 24 07:05:13 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290332, encodeId=cd8329033204, content=不错.学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=662c2267356, createdName=12198cffm94(暂无昵称), createdTime=Sat Feb 24 01:10:17 CST 2018, time=2018-02-24, status=1, ipAttribution=)]
    2018-02-24 12198cffm94(暂无昵称)

    不错.学习一下

    0

相关指南

2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理

亚洲克罗恩病和结肠炎组织(AOCC,Asian Organization for Crohn’s and Colitis) · 2017-10-10

2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估

亚洲克罗恩病和结肠炎组织(AOCC,Asian Organization for Crohn’s and Colitis) · 2017-10-10

2017 共识声明：抗肿瘤坏死因子治疗炎症性肠病治疗药物监测

国外消化科相关专家小组（统称） · 2017-10-13

抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)

中华医学会消化病学分会炎症性肠病学组 · 2017-08-30

建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见

中华医学会消化病学分会炎症性肠病学组 · 2017-06-20

炎症性肠病合并机会性感染专家共识意见

中华医学会消化病学分会炎症性肠病学组 · 2017-04-20